Employing PSI™ to summarize complex single-cell cytokine data

See how PSI corelates with objective response across cancer immunotherapies and is accelerating discovery and development.

Your data is in safe hands: we'll never sell it to third parties and you may always unsubscribe. Privacy Policy.

Employing PSI™ to summarize complex single-cell cytokine data

IsoPlexis’ Polyfunctional Strength Index (PSI) is a powerful, novel metric for measuring the potency of a variety of immune cell types in cancer immunotherapy, based on the ability to uniquely isolate & detect potent functional cell subsets.

In this Tech Note we:
  • Polyfunctionality alone is a meaningful indicator of potency in a variety of immunotherapy types, including CAR T therapy, where PSI has significantly outperformed other pre-infusion metrics.
  • Many researchers are also using sub-components of the PSI to develop a sub-component polyfunctional strength cell subset driver, such as IL-17 or Stimulatory driven Polyfunctional Strength.
  • The PSI Index reveals aggregate differences that guide your deep dive into polyfunctional cell subsets, via single-cell heat maps and cellular analyses like PAT PCA and t-SNE, that can reveal biomarkers and development insights.
2019-09-04T16:52:33+00:00